The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지
DOI QR코드

DOI QR Code

Plasminogen Activator Inhibitor-1 Antisense Oligodeoxynucleotides Abrogate Mesangial Fibronectin Accumulation

  • Park, Je-Hyun (Department of Bioinspired Science, Division of Life and Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University) ;
  • Seo, Ji-Yeon (Department of Bioinspired Science, Division of Life and Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University) ;
  • Ha, Hun-Joo (Department of Bioinspired Science, Division of Life and Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University)
  • Received : 2010.10.10
  • Accepted : 2010.11.06
  • Published : 2010.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Excessive extracellular matrix (ECM) accumulation is the main feature of chronic renal disease including diabetic nephropathy. Plasminogen activator inhibitor (PAI)-1 is known to play an important role in renal ECM accumulation in part through suppression of plasmin generation and matrix metalloproteinase (MMP) activation. The present study examined the effect of PAI-1 antisense oligodeoxynucleotide (ODN) on fibronectin upregulation and plasmin/MMP suppression in primary mesangial cells cultured under high glucose (HG) or transforming growth factor (TGF)-${\beta}1$, major mediators of diabetic renal ECM accumulation. Growth arrested and synchronized rat primary mesangial cells were transfected with $1\;{\mu}M$ phosphorothioate-modified antisense or control mis-match ODN for 24 hours with cationic liposome and then stimulated with 30 mM D-glucose or 2 ng/ml TGF-${\beta}1$. PAl-1 or fibronectin protein was measured by Western blot analysis. Plasmin activity was determined using a synthetic fluorometric plasmin substrate and MMP-2 activity analyzed using zymography. HG and TGF-${\beta}1$ significantly increased PAI-1 and fibronectin protein expression as well as decreased plasmin and MMP-2 activity. Transient transfection of mesangial cells with PAI-1 antisense ODN, but not mis-match ODN, effectively reversed basal as well as HG- and TGF-${\beta}1$-induced suppression of plasmin and MMP-2 activity. Both basal and upregulated fibronectin secretion were also inhibited by PAI-1 antisense ODN. These data confirm that PAI-1 plays an important role in ECM accumulation in diabetic mesangium through suppression of protease activity and suggest that PAI-1 antisense ODN would be an effective therapeutic strategy for prevention of renal fibrosis including diabetic nephropathy.

Keywords

References

  1. Steffes MW, Osterby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes. 1989;38:1077-1081. https://doi.org/10.2337/diabetes.38.9.1077
  2. Schnaper HW. Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis. Pediatr Nephrol. 1995;9:104-111.
  3. Wong AP, Cortez SL, Bariros WH. Role of plasmin and gelatinase in extracellular matrix degradation by cultured rat mesangial cells. Am J Physiol. 1992;263:F1112-F1118.
  4. Baricos WH, Cortez SL, Deboisblanc M, Xin S. Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol. 1999;10:790-795.
  5. Monea S, Lehti K, Keski-Oja J, Mignatti P. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol. 2002;192:160-170. https://doi.org/10.1002/jcp.10126
  6. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest. 1991;88:1067-1072. https://doi.org/10.1172/JCI115405
  7. Rerolle JP, Hertig A, Nguyen G, Sraer JD, Rondeau EP. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int. 2000;58:1841-1850. https://doi.org/10.1111/j.1523-1755.2000.00355.x
  8. Ingelfinger JR. Forestalling fibrosis. N Engl J Med. 2003;349:2265-2266. https://doi.org/10.1056/NEJMcibr032288
  9. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol. 2006;17:2999-3012. https://doi.org/10.1681/ASN.2006050503
  10. Ha H, Oh EY, Lee HB. The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol. 2009;5:203-211. https://doi.org/10.1038/nrneph.2009.15
  11. Lee EA, Seo .JY, Jiang Z, Yu MR, Kwon MK, Ha H, Lee HB. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up.regulation in mesangial cells and in diabetic kidney. Kidney Int. 2005;67:1762-1771. https://doi.org/10.1111/j.1523-1755.2005.00274.x
  12. Kitching AR, Kong YZ, Huang XR, Davenport P, Edgtton KL, Carmeliet P, Holdsworth SR, Tipping PG. Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis. J Am Soc Nephrol. 2003;14:1487-1495. https://doi.org/10.1097/01.ASN.0000065550.13931.00
  13. Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, Eddy AA. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int. 2001;60:587-596. https://doi.org/10.1046/j.1523-1755.2001.030002587.x
  14. Nicholas SB, Aguiniga E, Ren Y, Kim J, Wong J, Govindarajan N, Noda M, Wang W, Kawano Y, Collins A, Hsueh WA. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int. 2005;67:1297-1307. https://doi.org/10.1111/j.1523-1755.2005.00207.x
  15. Collins SJ, Alexander SL, Lopez-Guisa JM, Cai X, Maruvada R, Chua SC, Zhang G, Okamura DM, Matsuo S, Eddy AA. Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice. Nephrol. Exp Nephrol. 2006;104:e23-e34. https://doi.org/10.1159/000093673
  16. Seo JY, Park J, Yu MR. Kim YS, Ha H, Lee HB. Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta 1 during renal fibrosis in diabetes. Am J Nephrol. 2009;30:481-490. https://doi.org/10.1159/000242477
  17. Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest. 2003;112:379-388. https://doi.org/10.1172/JCI18038
  18. Huang Y, Border WA, Yu L, Zhang J, Lawrence DA, Noble NA. A PAI-l mutant. PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol. 2008;19:329-338. https://doi.org/10.1681/ASN.2007040510
  19. Huang Y, Border WA, Lawrenre DA, Noble NA. Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1(PAI-1R) in experimental nephritis. Am J Physiol Renal Physiol. 2009;297:F1045-F1054. https://doi.org/10.1152/ajprenal.00024.2009
  20. Neckers L, Whitesell L. Antisense technology: biological utility and practical considerations. Am J Physiol. 1993;265:L1-L12. https://doi.org/10.1152/ajpcell.1993.265.1.C1
  21. de Martimprey H, Vauthier C, Malvy C, Couvreur P. Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA Eur J Pharm Biopharm. 2009;71:490-504. https://doi.org/10.1016/j.ejpb.2008.09.024
  22. Cho HK, Yang EK, Han HS, Lee WJ, Phillips ML. Effect of brain angiotensin II receptor antagonists and antisense oligonucleotide on drinking and renal renin in rats. Korean J Physiol Pharmacol. 2000;4:137-142.
  23. Oh JH, Ha H, Yu MR, Lee HB. Sequential effects of high glucose on mesangial cell transforming growth factor-beta 1 and fibronectin synthesis. Kidney Int. 1998;54:1872-1878. https://doi.org/10.1046/j.1523-1755.1998.00193.x
  24. Jiang Z, Seo JY, Ha H, Lee EA, Kim YS, Han DC, Uh ST, Park CS, Lee HB. Reactive oxygen species mediate TGF-beta1-induced plasminogen activator inhibitor-1 upregulation in mesangial cells. Biochem Biophys Res Commun. 2003;309:961-966. https://doi.org/10.1016/j.bbrc.2003.08.102
  25. Fisher EJ, McLennan SV, Yue DK, Turtle JR. High glucose reduces generation of plasmin activity by mesangial cells. Microvasc Res. 1997;53:173-178. https://doi.org/10.1006/mvre.1996.2006
  26. Kanalas JJ, Hopfer U. Effect of TGF-beta 1 and TNF-alpha on the plasminogen system of rat proximal tubular epithelial cells. J Am Soc Nephrol. 1997;8:184-192.
  27. Gonzalez J, Klein J, Chauhan SD, Neau E, Calise D, Nevoit C, Chaaya R, Miravete M, Delage C, Bascands JL, Schanstra JP, Buffin-Meyer B. Delayed treatment with plasminogen activator inhibitor-1 decoys reduces tubulointerstitial fibrosis. Exp Biol Med (Maywood). 2009;234:1511-1518. https://doi.org/10.3181/0903-RM-105
  28. Sawa H, Sobel BE, Fujii S. Inhibition of type-1 plasminogen activator inhibitor production by antisense oligonucleotides in human vascular endothelial and smooth muscle cells. J Biol Chem. 1994;269:14149-14152.

Cited by

  1. Glibenclamide Induces Collagen IV Catabolism in High Glucose-Stimulated Mesangial Cells vol.2012, pp.None, 2010, https://doi.org/10.1155/2012/183535
  2. Delayed Treatment With Human Umbilical Cord Blood-Derived Stem Cells Attenuates Diabetic Renal Injury vol.44, pp.4, 2010, https://doi.org/10.1016/j.transproceed.2012.03.044